Retinal Biologics Market

Retinal Biologics Market: Extensive Prescription of Anti-VEGF Drugs in Ophthalmic Diseases Treatment to Aid Substantial Revenue Generation: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

2019-01-25
REP-GB-8663
33 Tables
107 Figures
194 pages

Home
Market Research Reports
Healthcare, Pharmaceuticals and Medical devices
Retinal Biologics Market

An Incisive, In-depth Analysis on the Retinal Biologics Market

This study offers a comprehensive, 360 degree analysis on the Retinal Biologics market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Retinal Biologics market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Request a sample

Ask An Analyst

Request Special Price

Request Methodology

VEGF-A Antagonist Prescription for Treatment of Neovascular Age-Related Macular Degeneration to Drive Retinal Biologics Market Growth

Many retinal biologics have been approved by the Food and Drug Administration (FDA), the European Medicine Agency (EMA) and the China Food and Drug Administration (CFDA) for the treatment of retinal diseases. Advancements in technologies and new mechanism of action for different biologics to treat retinal diseases are anticipated to boost the retinal biologics market. VEGF-A antagonist has been the prime focus area for many manufacturers as it prevents angiogenesis. For example, Eylea, manufactured by Regeneron, and Lucentis, manufactured by Roche, with anti-VEGF inhibitor, are available in the market for the treatment of neovascular age-related macular degeneration.

Rising Burden of Retinal Diseases and Increasing Diabetic Patient Population to Push Retinal Biologics Market Growth

Diabetic retinopathy has been a rising concern as the disease leads to vision loss among Type I and Type II adult diabetic patients. Diabetic macular edema also results from the consequences of diabetic retinopathy, which leads to the swelling of macula. According to Prevent Blindness statistics, the prevalence of diabetic retinopathy in the U.S. is estimated to be 5.3%. VEGF-A antagonist is largely prescribed for the diabetic retinopathy treatment and also for treatment of diabetic macular edema. These factors are expected to propel the growth of the retinal biologics market. Moreover, the increasing burden of other retinal diseases such as uveitis and orbital inflammation is another factor surging the demand for retinal drugs and biologics.

First FDA Approved Gene Therapy Likely to Drive Market Growth

Retinal gene therapy is a therapeutic approach wherein the inherited defective genes are replaced by treatment with DNA or RNA. Gene therapy is considered to be a significant approach as there occurs less contamination, and the viral vector can easily accommodate within the eyes. In December 2017, Spark Therapeutics’ first ever gene therapy developed from adeno associated virus, known as Luxturna, received approval from the FDA in the treatment of patients with mutation associated retinal dystrophy. Many ophthalmic physicians are now inclined towards the use of gene therapy, which is expected to drive the growth of the global retinal biologics market.

Licensing and Collaboration Agreements among Major Players to Expand Product Footprint

Multiple companies are entering into licensing and collaboration agreements to expand their products into various countries worldwide in order to cater to the unmet demand. For example, in January 2018, Spark Therapeutics and Novartis Pharma AG received marketing authorization from the European Commission for Luxturna in the treatment of mutation associated with retinal dystrophy. In order to improve the pipeline portfolio in research and development, many companies have entered into collaboration agreements with various other companies and universities, which in turn is expected to drive the market for retinal biologics during the forecast period.

Competitive Landscape of Global Retinal Biologics Market

The competition section of the retinal biologics market provides detailed information about key players competing in the retinal biologics market based on their market shares, market strategies, product offerings, marketing approach and company dashboard. Some of the key players featured in this retinal biologics market report include Spark Therapeutics, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., AbbVie Inc., Johnson & Johnson Services, Inc. and Amgen Inc.

Definition

Retinal biologics are bioengineered molecules that are implanted inside the eyes to heal chronic retinal diseases. Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Some of the retinal biologics used in retinal diseases are Eylea, Lucentis, Humira, Macugen and others.

About the Report

The company has conducted a research study on the retinal biologics market for the forecast period 2018 to 2028, which provides a thorough assessment of opportunities in the retinal biologics market along with an understanding of the populations at risk, pipeline assessment analysis and epidemiology analysis about retinal biologics and competition in the retinal biologics market. Further, the report provides thorough information regarding the macroeconomic factors impelling the dynamics in the retinal biologics market.

Segmentation

The report offers a taxonomy of the retinal biologics market. The retinal biologics market has been segmented on the basis of drug class, indication, distributional channel and region. It has been segmented on the basis of drug class into VEGF-A antagonist and TNF-α inhibitor. The retinal biologics market has been segmented on the basis of indication into macular degeneration, diabetic macular edema, diabetic retinopathy, uveitis and others. By distributional channel, the retinal biologics market has been segmented into institutional sales and retail sales. The institutional sales segment of the report has been further categorized into specialty clinics and hospitals while the retail sales segment has been sub-segmented into retail pharmacies and mail order pharmacies.

Additional Questions Answered

Some of the additional questions answered in this report on retinal biologics market are:

What is the revenue potential of the retinal biologics market across North America and Europe?
Who are the key players and what are their product portfolios in the retinal biologics market?
What are the major challenges impacting the growth of the retinal biologics market?
What are the reimbursement guidelines for retinal biologics prescriptions?

Research Methodology

The retinal biologics market has been studied from a supply-demand side approach. Further, qualitative factors impacting the retinal biologics market, such as awareness regarding retinal biologics and treatments available, cost of treatment, reimbursement scenario and others, have also been discussed in the market report. The calculated data has been further validated through primary research, including telephonic interviews, surveys, in-person interactions and viewpoints of experienced analysts. Secondary research resources, such as databases, trade journals and verified paid sources, were used to arrive at the observations drawn. The research study on the retinal biologics market also includes prominent trends and macro as well as microeconomic factors influencing the retinal biologics market.

FMI’s recently published report titled ‘Retinal Biologics Market: Global Industry Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028' offers a comprehensive assessment of the key dynamics pertaining to the retinal biologics market. The report presents growth prospects for the retinal biologics market, which have been obtained with maximum precision through detailed research on the historic as well as current growth parameters.

The report discusses the prominent factors that are likely to have a significant impact on the development of the retinal biologics market during the forecast period. This information will prove to be key for market players to modify their manufacturing and marketing strategies and envisage maximum growth in the retinal biologics market in the coming years.

Chapter 1 – Executive Summary

The report commences with an executive summary, which comprises a summary of the key findings and statistics pertaining to the retinal biologics market. This section also provides market value (US$ Million) estimates for the leading segments of the retinal biologics market.

Chapter 2 – Market Overview

Readers can find a detailed taxonomy and definitions in this chapter to help them better understand the basic information about the retinal biologics market dynamics, pricing analysis, list of key manufacturers and key regulation policies included in the succeeding sections of the report.

Chapter 3 – Global Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028 by Drug Class

On the basis of drug class, the retinal biologics market has been segmented into VEGF-A antagonist and TNF-α inhibitor. In this chapter, readers can find information about the key trends and developments observed in the retinal biologics market. The section also comprises a market attractiveness analysis of the segments on the basis of drug class.

Chapter 4 – Global Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028 by Indication

Based on indication, the retinal biologics market has been segmented into macular degeneration, diabetic retinopathy, diabetic macular edema, uveitis and others. In this section, readers can find information about device usage, key trends and technological developments in the retinal biologics market along with a market attractiveness analysis of the key segments based on indication.

Chapter 5 – Global Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028 by Distribution Channel

By distributional channel, the retinal biologics market has been segmented into institutional sales, which has further been sub-segmented into specialty clinics and hospitals and retail sales, which has further been sub-segmented into retail pharmacies and mail order pharmacies. In this chapter, readers can find information about the key trends and developments identified in the retinal biologics market and a market attractiveness analysis of the key segments based on distributional channel.

Chapter 6 – Global Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028 by Region

This chapter explains how the retinal biologics market is expected to grow across various geographic regions, such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and the Middle East & Africa (MEA).

Chapter 7 – North America Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

This chapter includes a detailed analysis of the growth of the retinal biologics market, along with a country-wise assessment for various countries in North America, including the U.S. and Canada. Readers can also find information on regional trends, macro-economic factors and market growth on the basis of drug class, indication, distributional channel and country for the retinal biologics market in North America.

Chapter 8 – Latin America Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find detailed information about pricing analysis and regional trends impacting the growth of the Latin American retinal biologics market. This chapter also discusses growth prospects for the retinal biologics market in leading LATAM countries, such as Brazil, Mexico and the Rest of the Latin America.

Chapter 9 – Western Europe Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find detailed information about the important growth parameters in the retinal biologics market in several European countries, such as Germany, the U.K., France, Italy, Spain and the rest of Western Europe.

Chapter 10 – Eastern Europe Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find detailed information about the important growth parameters in the retinal biologics market for several European countries, such as the Russia, Poland and rest of Eastern Europe.

Chapter 11 – APEJ Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find thorough information about the various parameters expected to impact the APEC retinal biologics market during the forecast period 2018 – 2028. China, India, Australia and New Zealand, ASEAN, rest of APAC are the leading countries/regions in APEJ and hence, the prime subject of assessment in this chapter.

Chapter 12 – Japan Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find information on the important factors expected to make a significant impact on the growth of the retinal biologics market in Japan during the forecast period 2018 – 2028. This chapter provides an overview of the drivers, restraints and trends prevailing in the Japan retinal biologics market.

Chapter 13 – MEA Retinal Biologics Market Analysis 2013 – 2017 & Opportunity Assessment 2018 – 2028

Readers can find detailed information on how the retinal biologics market is expected to grow in major countries/regions of the MEA region, such as GCC Countries, South Africa, and the Rest of MEA during the period 2018 – 2028.

Chapter 14 – Competition Landscape, Company Share, and Company Profiles

In this chapter, readers can find a comprehensive list of all leading stakeholders in the retinal biologics market and detailed information about each company, including company overview, offered products, SWOT analysis, key strategy and recent company developments. The market players featured in the report include Spark Therapeutics, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., AbbVie Inc., Johnson & Johnson Services, Inc. and Amgen Inc.

Chapter 15 – Assumptions and Acronyms

This chapter of the retinal biologics market report includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 16 – Research Methodology

This chapter help readers understand the research methodology followed to obtain various conclusions, important qualitative information and quantitative information about the retinal biologics market.